Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1350

1.

The impact of prevention on reducing the burden of cardiovascular disease.

Kahn R, Robertson RM, Smith R, Eddy D.

Circulation. 2008 Jul 29;118(5):576-85. doi: 10.1161/CIRCULATIONAHA.108.190186. Epub 2008 Jul 7.

PMID:
18606915
[PubMed - indexed for MEDLINE]
Free Article
2.

The impact of prevention on reducing the burden of cardiovascular disease.

Kahn R, Robertson RM, Smith R, Eddy D.

Diabetes Care. 2008 Aug;31(8):1686-96. doi: 10.2337/dc08-9022. Review.

PMID:
18663233
[PubMed - indexed for MEDLINE]
Free PMC Article
3.
4.

Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.

Whitfield MD, Gillett M, Holmes M, Ogden E.

Public Health. 2006 Dec;120(12):1140-8. Epub 2006 Nov 3.

PMID:
17084425
[PubMed - indexed for MEDLINE]
5.

Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.

Liew D, Park HJ, Ko SK.

Clin Ther. 2009 Oct;31(10):2189-203; discussion 2150-1. doi: 10.1016/j.clinthera.2009.10.015.

PMID:
19922890
[PubMed - indexed for MEDLINE]
6.

Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence.

Daviglus ML, Lloyd-Jones DM, Pirzada A.

Am J Cardiovasc Drugs. 2006;6(2):87-101. Review.

PMID:
16555862
[PubMed - indexed for MEDLINE]
7.

Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach.

Jackson R.

J Hum Hypertens. 1998 Sep;12(9):607-13. Review.

PMID:
9783489
[PubMed - indexed for MEDLINE]
8.

Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.

Huse DM, Song X, Ozminkowski RJ, Maguire J, Williams SA, Borok GM, McDonough K.

Clin Ther. 2006 Sep;28(9):1425-42.

PMID:
17062315
[PubMed - indexed for MEDLINE]
9.

The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?

Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L.

Arch Intern Med. 2003 Feb 10;163(3):333-9.

PMID:
12578514
[PubMed - indexed for MEDLINE]
10.

Effect of smoking cessation advice on cardiovascular disease.

Eddy DM, Peskin B, Shcheprov A, Pawlson G, Shih S, Schaaf D.

Am J Med Qual. 2009 May-Jun;24(3):241-9. doi: 10.1177/1062860609332509. Epub 2009 Mar 30.

PMID:
19332865
[PubMed - indexed for MEDLINE]
11.

The relative impact of inadequate primary and secondary prevention on cardiovascular mortality in the United States.

Qureshi AI, Suri MF, Kirmani JF, Divani AA.

Stroke. 2004 Oct;35(10):2346-50. Epub 2004 Sep 2.

PMID:
15345797
[PubMed - indexed for MEDLINE]
Free Article
12.

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.

Ghandehari H, Kamal-Bahl S, Wong ND.

Am Heart J. 2008 Jul;156(1):112-9. doi: 10.1016/j.ahj.2008.03.005. Epub 2008 May 15.

PMID:
18585505
[PubMed - indexed for MEDLINE]
13.

Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults, 1971-2002.

Kanjilal S, Gregg EW, Cheng YJ, Zhang P, Nelson DE, Mensah G, Beckles GL.

Arch Intern Med. 2006 Nov 27;166(21):2348-55.

PMID:
17130388
[PubMed - indexed for MEDLINE]
14.

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.

Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L.

Intern Med. 2007;46(4):157-62. Epub 2007 Feb 15.

PMID:
17301509
[PubMed - indexed for MEDLINE]
Free Article
15.

Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.

Sorensen SV, Frick KD, Wade A, Simko R, Burge R.

Clin Ther. 2009 Apr;31(4):862-79. doi: 10.1016/j.clinthera.2009.04.015.

PMID:
19446159
[PubMed - indexed for MEDLINE]
16.

Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.

Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB.

Lancet. 2003 Mar 1;361(9359):717-25. Erratum in: Lancet. 2005 Jul 16-22;366(9481):204.

PMID:
12620735
[PubMed - indexed for MEDLINE]
17.

Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.

Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J.

Clin Ther. 2008 Aug;30(8):1508-23. doi: 10.1016/j.clinthera.2008.08.002.

PMID:
18803993
[PubMed - indexed for MEDLINE]
18.

Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System.

Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH.

Am J Prev Med. 2006 Jan;30(1):74-7.

PMID:
16414427
[PubMed - indexed for MEDLINE]
19.

Impact and cost-effectiveness of smoking interventions.

Tsevat J.

Am J Med. 1992 Jul 15;93(1A):43S-47S. Review.

PMID:
1497003
[PubMed - indexed for MEDLINE]
20.

Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis.

Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R.

Diabetes Care. 2009 Feb;32(2):361-6. doi: 10.2337/dc08-0854. Epub 2008 Nov 18.

PMID:
19017770
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk